GO:0015052 beta3-adrenergic receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015052 beta3-adrenergic receptor activity is a molecular function defined as binding epinephrine or norepinephrine to initiate G protein-mediated signaling with the pharmacological profile of beta3-adrenergic receptors.
• The receptor is encoded by ADRB3 and is best known for its role in brown/beige adipocyte lipolysis and thermogenesis.
• Selective beta3 agonists such as mirabegron have been tested in humans and rodents for metabolic, cardiovascular and hepatic indications.
• Beta3-adrenergic signaling also modulates human myometrial relaxation via connexin 43 and has been proposed as a target in autosomal dominant polycystic kidney disease.
• Studying this function requires tools that can distinguish beta3 from beta1/beta2 subtypes, including selective agonists, antagonists and genetic models.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models allow causal testing of ADRB3 variants and downstream signaling in relevant cell types.
Description
GO:0015052 beta3-adrenergic receptor activity is a molecular function in the Gene Ontology that describes the binding of epinephrine or norepinephrine to a receptor that initiates a change in cell activity via activation of a G protein, with the pharmacological characteristics of beta3-adrenergic receptors. This activity is distinct from beta1- and beta2-adrenergic receptor activities and is classically associated with atypical beta-adrenergic responses in adipose tissue and other organs. The receptor responsible for this activity is ADRB3, a G protein-coupled receptor that has become a focus for metabolic and cardiovascular research because of its role in energy expenditure and vascular biology. Interest in beta3-adrenergic receptor activity has grown with the clinical availability of selective agonists such as mirabegron. In humans, mirabegron activates brown adipose tissue and stimulates lipolysis and thermogenesis in brown/beige adipocytes. In preclinical models, beta3-adrenergic receptor activation by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue, alleviates PM2.5-induced hepatic lipid deposition, and has been proposed as a therapeutic strategy in autosomal dominant polycystic kidney disease. These findings position GO:0015052 as a functionally important node linking catecholamine signaling to metabolic, vascular and renal physiology. For researchers, GO:0015052 provides a precise annotation target for experiments that aim to separate beta3-adrenergic signaling from other adrenergic pathways. Because beta3-adrenergic receptors can couple to G proteins and modulate downstream effectors in a cell-type-specific manner, functional studies benefit from selective pharmacology and genetic models. This article summarizes the definition, mechanism, key genes, disease relevance and research methods for GO:0015052, with all factual statements supported by the verified literature listed below.
beta3-adrenergic receptor activity At A Glance
| GO ID | GO:0015052 |
|---|---|
| GO term | beta3-adrenergic receptor activity |
| Ontology | molecular_function |
| Synonym | beta3 adrenoceptor |
| Definition | Combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta3-adrenergic receptors. |
| Major function | Catecholamine sensing and G protein-mediated signal initiation with beta3-adrenergic pharmacology |
| Representative gene | ADRB3 |
| Typical ligands | Epinephrine and norepinephrine |
| Therapeutic relevance | Metabolic, cardiovascular, hepatic and renal indications studied with selective beta3 agonists |
What Is GO:0015052?
In plain terms, GO:0015052 beta3-adrenergic receptor activity means that a receptor binds epinephrine or norepinephrine and then triggers a G protein-dependent change inside the cell, with the behavior expected of a beta3-adrenergic receptor. The QuickGO definition specifies that the response must have the pharmacological characteristics of beta3-adrenergic receptors, distinguishing this activity from beta1- and beta2-adrenergic receptor activities. The synonym beta3 adrenoceptor refers to the same function. This is a molecular_function term, so it describes what the receptor does at the molecular level rather than a whole biological process or a cellular location.
Why Is beta3-adrenergic receptor activity Important in Cell Biology?
GO:0015052 is important because beta3-adrenergic receptor activity is a druggable node that connects catecholamines to energy expenditure, vascular remodeling, myometrial relaxation and lipid handling. Selective beta3 agonists such as mirabegron have been shown to activate human brown adipose tissue and stimulate brown/beige adipocyte lipolysis and thermogenesis, and beta3-adrenergic receptor activation has been reported to prevent aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. Additional studies link this activity to reduced PM2.5-induced hepatic lipid deposition and to a potential therapeutic role in autosomal dominant polycystic kidney disease. Because beta3-adrenergic pharmacology differs from that of beta1- and beta2-adrenergic receptors, accurate annotation and experimental separation of GO:0015052 are essential for interpreting adrenergic drug effects.
• Controls brown/beige adipocyte lipolysis and thermogenesis in humans.
• Mediates vascular protection in aortic dissection/aneurysm models via perivascular adipose tissue lymphangiogenesis.
• Modulates human myometrial relaxation through connexin 43 activity.
• Is implicated in hepatic lipid deposition under PM2.5 exposure in mice.
• Is proposed as a therapeutic target in autosomal dominant polycystic kidney disease.
• Is a candidate anti-obesity target through selective beta3-adrenergic receptor agonism.
• Provides a pharmacological signature that distinguishes beta3 from beta1/beta2 adrenergic receptors.
• Supports energy expenditure research relevant to metabolic disease.
• Enables mechanistic dissection of G protein-coupled signaling in diverse cell types.
• Offers a genetically tractable function for CRISPR knockout, point-mutation, knock-in and overexpression studies.
Molecular Mechanism of beta3-adrenergic receptor activity
Ligand binding and receptor activation
In simple terms: The receptor first catches epinephrine or norepinephrine, which flips it into an active state.
GO:0015052 requires combining with epinephrine or norepinephrine to initiate a change in cell activity via activation of a G protein, with pharmacological characteristics of beta3-adrenergic receptors. Selective beta3 agonists such as mirabegron can substitute for catecholamines in experimental and clinical settings, as shown by activation of human brown adipose tissue and by prevention of aortic dissection/aneurysm in mice. The pharmacological distinction from beta1- and beta2-adrenergic receptors is central to the definition and to the interpretation of beta-blocker class differences.
G protein coupling and downstream signaling
In simple terms: Once active, the receptor turns on a G protein, which relays the signal inside the cell.
The QuickGO definition specifies that beta3-adrenergic receptor activity initiates a change in cell activity via activation of a G protein. Downstream effects reported in the verified literature include regulation of human brown/beige adipocyte lipolysis and thermogenesis, modulation of connexin 43 activity to relax human myometrium, and alleviation of PM2.5-induced hepatic lipid deposition in mice. These outcomes are consistent with G protein-dependent signaling but should be interpreted in the context of the specific cell type and agonist used.
Tissue-specific effector responses
In simple terms: Different tissues respond to the same receptor signal in different ways.
In adipose tissue, beta3-adrenergic receptor activation regulates human brown/beige adipocyte lipolysis and thermogenesis and human brown adipose tissue activation has been demonstrated with a beta3-adrenergic receptor agonist. In the vasculature, activation by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. In the liver, beta3-adrenergic receptor activation alleviated PM2.5-induced hepatic lipid deposition in mice. In the myometrium, beta3-adrenergic receptor activation modulates connexin 43 activity to relax human myometrium. In the kidney, the beta3-adrenergic receptor has been proposed as a potential therapeutic target in autosomal dominant polycystic kidney disease.
Pharmacological selectivity and class differences
In simple terms: Beta3 receptors are not the same as beta1 or beta2 receptors, so drugs can be designed to hit one subtype more than others.
The definition of GO:0015052 explicitly requires pharmacological characteristics of beta3-adrenergic receptors, which separates this activity from other beta-adrenergic receptor activities. The three generations of beta-blockers differ in their receptor selectivity and clinical applicability, and this history informs how beta3-selective agonists such as mirabegron are positioned. Mirabegron is described as a selective beta3-adrenergic receptor agonist with potential as an anti-obesity drug, and its use in preclinical models of aortic disease and hepatic lipid deposition illustrates how subtype selectivity shapes experimental design.
Regulation of receptor output
In simple terms: The strength and duration of the signal can be tuned by the cell.
The verified literature supports context-dependent regulation of beta3-adrenergic receptor activity. For example, beta3-adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis, and beta3-adrenergic receptor activation modulates connexin 43 activity in human myometrium. In disease models, beta3-adrenergic receptor activation by mirabegron promotes lymphangiogenesis in perivascular adipose tissue to prevent aortic dissection/aneurysm, and beta3-adrenergic receptor activation alleviates PM2.5-induced hepatic lipid deposition in mice. These observations indicate that the functional output of GO:0015052 depends on tissue context and the presence of selective agonists.
Key Genes Involved in GO:0015052 beta3-adrenergic receptor activity
The following genes and proteins are directly or functionally associated with GO:0015052 beta3-adrenergic receptor activity in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB3 | Encodes the beta3-adrenergic receptor that carries GO:0015052 activity | Central to all studies of beta3-adrenergic receptor function and pharmacology |
| ADRB1 | Encodes beta1-adrenergic receptor, a related but pharmacologically distinct subtype | Used as a comparator in beta-blocker class studies |
| ADRB2 | Encodes beta2-adrenergic receptor, a related but pharmacologically distinct subtype | Used as a comparator in beta-blocker class studies |
| GNAI1 | Encodes a G protein alpha subunit that can couple to adrenergic receptors | Relevant to G protein-dependent signaling described in the GO definition |
| GNAS | Encodes the stimulatory G protein alpha subunit | Relevant to G protein-dependent signaling described in the GO definition |
| GJA1 | Encodes connexin 43, whose activity is modulated by beta3-adrenergic receptor activation | Studied in human myometrial relaxation |
| UCP1 | Uncoupling protein 1, a thermogenic effector in brown/beige adipocytes | Downstream marker of beta3-adrenergic thermogenesis |
| LIPE | Hormone-sensitive lipase involved in adipocyte lipolysis | Downstream marker of beta3-adrenergic lipolysis |
| PNPLA2 | Adipose triglyceride lipase involved in lipolysis | Downstream marker of beta3-adrenergic lipolysis |
| VEGFC | Lymphangiogenic growth factor | Linked to beta3-adrenergic promotion of lymphangiogenesis in perivascular adipose tissue |
| PKD1 | Gene mutated in autosomal dominant polycystic kidney disease | Context for beta3-adrenergic receptor targeting in ADPKD |
| PKD2 | Gene mutated in autosomal dominant polycystic kidney disease | Context for beta3-adrenergic receptor targeting in ADPKD |
| PRKAA1 | AMP-activated protein kinase catalytic subunit alpha 1 | Potential downstream metabolic node in beta3-adrenergic signaling |
| PRKAA2 | AMP-activated protein kinase catalytic subunit alpha 2 | Potential downstream metabolic node in beta3-adrenergic signaling |
| CREB1 | Transcription factor responsive to cAMP signaling | Potential downstream effector of G protein-coupled beta3-adrenergic signaling |
| PPARA | Peroxisome proliferator-activated receptor alpha | Relevant to hepatic lipid handling in beta3-adrenergic studies |
| PPARG | Peroxisome proliferator-activated receptor gamma | Relevant to adipocyte biology in beta3-adrenergic studies |
| NOS3 | Endothelial nitric oxide synthase | Potential vascular effector in beta3-adrenergic cardiovascular studies |
How Is beta3-adrenergic receptor activity Regulated?
The activity described by GO:0015052 is regulated at multiple levels, including ligand availability, receptor subtype selectivity and tissue context. The QuickGO definition requires binding of epinephrine or norepinephrine and activation of a G protein, so changes in catecholamine tone or G protein coupling directly affect the function. Pharmacological regulation is exemplified by selective beta3-adrenergic receptor agonists such as mirabegron, which activates human brown adipose tissue and prevents aortic dissection/aneurysm in mice. Beta-blocker class differences further illustrate how receptor selectivity modulates adrenergic signaling. In human myometrium, beta3-adrenergic receptor activation modulates connexin 43 activity to relax the tissue, showing that regulation can occur through downstream effectors. In metabolic and hepatic contexts, beta3-adrenergic receptor activation regulates brown/beige adipocyte lipolysis and thermogenesis and alleviates PM2.5-induced hepatic lipid deposition in mice. In ADPKD, the beta3-adrenergic receptor has been proposed as a potential therapeutic target, implying disease-specific regulation. Mirabegron has also been discussed as a potential anti-obesity drug, highlighting pharmacological regulation of this activity.
beta3-adrenergic receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB3 | Aortic dissection/aneurysm | Mouse aortic injury model with mirabegron treatment |
| ADRB3 | Obesity and thermogenesis | Human brown/beige adipocyte cultures and human brown adipose tissue activation studies |
| ADRB3 | PM2.5-induced hepatic lipid deposition | Mouse exposure model with beta3-adrenergic receptor activation |
| ADRB3 | Autosomal dominant polycystic kidney disease | ADPKD cell and animal models with beta3-adrenergic receptor targeting |
| ADRB3 | Myometrial relaxation | Human myometrial tissue and connexin 43 activity assays |
Cardiovascular disease: aortic dissection and aneurysm
Activation of beta3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue. This finding links GO:0015052 to vascular remodeling and suggests that selective beta3-adrenergic receptor agonism may be a therapeutic strategy in aortic disease. The study also positions perivascular adipose tissue as a key mediator of the protective effect.
Metabolic disease: obesity and thermogenesis
Beta3-adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis, and activation of human brown adipose tissue by a beta3-adrenergic receptor agonist has been demonstrated. Mirabegron, a selective beta3-adrenergic receptor agonist, has been discussed as a potential anti-obesity drug. These studies support a role for GO:0015052 in energy expenditure and metabolic disease.
Hepatic lipid deposition
Beta3-adrenergic receptor activation alleviated PM2.5-induced hepatic lipid deposition in mice. This connects GO:0015052 to environmental exposure and liver lipid metabolism, and suggests that beta3-adrenergic signaling may modulate hepatic steatosis under particulate matter stress.
Renal disease: autosomal dominant polycystic kidney disease
The beta3-adrenergic receptor has been proposed as a potential therapeutic target in autosomal dominant polycystic kidney disease. This extends the disease relevance of GO:0015052 beyond metabolic and cardiovascular contexts and supports further investigation of beta3-adrenergic signaling in renal cystogenesis.
From beta3-adrenergic receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADRB3 abolish beta3-adrenergic receptor activity? | ADRB3 knockout cell line or animal model |
| Does a specific ADRB3 variant alter G protein coupling? | Point-mutation knock-in of the variant in a relevant cell line |
| Can a selective agonist activate the receptor in a specific tissue? | Knock-in reporter or tagged ADRB3 model with agonist treatment |
| Does overexpression of ADRB3 enhance downstream lipolysis? | ADRB3 overexpression in adipocyte or heterologous cells |
| Which downstream effectors mediate myometrial relaxation? | Human myometrial cells with ADRB3 modulation and connexin 43 readout |
| Does beta3-adrenergic receptor activation protect against hepatic lipid deposition? | Mouse model with ADRB3 agonist and lipid measurements |
How to Study the beta3-adrenergic receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Selective agonist treatment | Activation of beta3-adrenergic receptor activity | Testing mirabegron or related agonists in cells and animals |
| Knockout models | Loss of ADRB3 function | Causal testing of beta3-adrenergic receptor activity in disease models |
| Point-mutation knock-in | Effect of specific ADRB3 variants | Linking genetic variation to receptor function |
| Overexpression | Gain of ADRB3 signaling | Enhancing downstream lipolysis or thermogenesis readouts |
| Lipolysis and thermogenesis assays | Brown/beige adipocyte function | Metabolic studies of beta3-adrenergic signaling |
| Connexin 43 activity assay | Myometrial relaxation signaling | Human myometrium studies |
| Lymphangiogenesis imaging | Perivascular adipose tissue remodeling | Aortic dissection/aneurysm models |
| Hepatic lipid measurement | Liver lipid deposition | PM2.5 exposure models |
Pharmacological profiling with selective agonists and antagonists
Because GO:0015052 is defined by pharmacological characteristics of beta3-adrenergic receptors, selective agonists such as mirabegron are essential tools. Mirabegron has been used to activate human brown adipose tissue, prevent aortic dissection/aneurysm in mice, and alleviate PM2.5-induced hepatic lipid deposition. Beta-blocker class differences provide additional pharmacological context for interpreting subtype selectivity.
Genetic models for causal testing
Knockout, point-mutation, knock-in and overexpression models allow researchers to test whether ADRB3 is causally involved in a given phenotype. Such approaches are relevant to studies of brown/beige adipocyte lipolysis and thermogenesis, myometrial relaxation, hepatic lipid deposition, aortic disease and ADPKD. Genetic models complement pharmacological studies by separating receptor-specific effects from off-target drug actions.
Downstream signaling and effector assays
Measuring G protein activation and downstream effectors helps confirm that a response is mediated by GO:0015052. Reported readouts include lipolysis and thermogenesis in human brown/beige adipocytes, connexin 43 activity in human myometrium, lymphangiogenesis in perivascular adipose tissue, and hepatic lipid deposition in mice. These assays should be interpreted with attention to cell type and agonist selectivity.
Human translational studies
Human studies provide direct evidence for beta3-adrenergic receptor activity in physiology. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist has been demonstrated, and beta3-adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis. The potential of mirabegron as an anti-obesity drug has also been reviewed. These translational studies help connect GO:0015052 to clinical phenotypes.
How CRISPR Can Be Used to Study GO:0015052 beta3-adrenergic receptor activity
Knockout
CRISPR knockout of ADRB3 can be used to test whether beta3-adrenergic receptor activity is required for a given phenotype. This is relevant to studies of brown/beige adipocyte lipolysis and thermogenesis, myometrial relaxation, hepatic lipid deposition, aortic disease and ADPKD. Knockout models help distinguish beta3-adrenergic receptor activity from other adrenergic receptor activities.
Point Mutation
CRISPR point mutation can introduce specific ADRB3 variants to test how sequence changes affect ligand binding, G protein coupling or downstream signaling. Such experiments are useful when pharmacological tools cannot separate closely related receptor subtypes. Point-mutation models can be combined with selective agonist treatment to probe beta3-adrenergic receptor pharmacology.
Knock-in
CRISPR knock-in can add tags or reporters to ADRB3 to track receptor expression, localization and activation in relevant tissues. Tagged knock-in models are useful for studying beta3-adrenergic receptor activity in brown adipose tissue, myometrium, perivascular adipose tissue and liver. Knock-in approaches also allow precise modeling of human variants in animal or cell systems.
Overexpression
CRISPR overexpression or transgenic overexpression of ADRB3 can amplify beta3-adrenergic receptor signaling to test gain-of-function phenotypes. This is relevant to lipolysis and thermogenesis studies in brown/beige adipocytes, to hepatic lipid handling, and to cardiovascular protection models. Overexpression should be interpreted alongside knockout and pharmacological data to avoid confounding from supraphysiological signaling.
How EDITGENE Supports beta3-adrenergic receptor activity Research
Researchers studying beta3-adrenergic receptor activity-related genes often need to determine whether a candidate gene is causally involved in a phenotype, whether a specific variant alters receptor function, or whether a selective agonist acts through ADRB3 rather than related adrenergic receptors. EDITGENE provides CRISPR-based cell models and screening services that support these questions with reproducible, publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for beta3-adrenergic receptor activity research.
Frequently Asked Questions About beta3-adrenergic receptor activity
What is GO:0015052 beta3-adrenergic receptor activity?
GO:0015052 is a molecular function term describing the binding of epinephrine or norepinephrine to a receptor that initiates a change in cell activity via activation of a G protein, with pharmacological characteristics of beta3-adrenergic receptors.
What gene encodes the beta3-adrenergic receptor?
The beta3-adrenergic receptor is encoded by ADRB3, which is the central gene for studies of GO:0015052.
What is the difference between beta3-adrenergic receptor activity and beta1 or beta2 activity?
The definition of GO:0015052 requires pharmacological characteristics of beta3-adrenergic receptors, which distinguishes it from beta1- and beta2-adrenergic receptor activities; beta-blocker class differences illustrate these distinctions.
What diseases are linked to beta3-adrenergic receptor activity?
Beta3-adrenergic receptor activity has been linked to aortic dissection/aneurysm, obesity and thermogenesis, PM2.5-induced hepatic lipid deposition, autosomal dominant polycystic kidney disease and myometrial relaxation.
How is beta3-adrenergic receptor activity activated experimentally?
Selective agonists such as mirabegron are used to activate beta3-adrenergic receptor activity in cells and animal models.
Does mirabegron activate human brown adipose tissue?
Yes, activation of human brown adipose tissue by a beta3-adrenergic receptor agonist has been demonstrated.
What role does beta3-adrenergic receptor activity play in lipolysis?
Beta3-adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.
Can CRISPR be used to study beta3-adrenergic receptor activity?
Yes, CRISPR knockout, point mutation, knock-in and overexpression models can be used to test the causal role of ADRB3 and downstream genes in beta3-adrenergic receptor activity.
What is the role of connexin 43 in beta3-adrenergic receptor activity?
Beta3-adrenergic receptor activation modulates connexin 43 activity to relax human myometrium.
Is beta3-adrenergic receptor activity a therapeutic target in kidney disease?
The beta3-adrenergic receptor has been proposed as a potential therapeutic target in autosomal dominant polycystic kidney disease.
Conclusion
GO:0015052 beta3-adrenergic receptor activity defines a specific molecular function in which epinephrine or norepinephrine binding to the beta3-adrenergic receptor initiates G protein-dependent signaling with a distinct pharmacological profile. The verified literature links this activity to brown/beige adipocyte lipolysis and thermogenesis, cardiovascular protection, hepatic lipid handling, myometrial relaxation and autosomal dominant polycystic kidney disease. Selective agonists such as mirabegron have become key tools for probing this function. For researchers, the combination of selective pharmacology and CRISPR-based genetic models offers a rigorous path to test causality and mechanism. Knockout, point-mutation, knock-in and overexpression models can resolve how ADRB3 and its downstream effectors contribute to disease-relevant phenotypes. EDITGENE supports these efforts with custom cell model generation, library screening and bioinformatics services tailored to beta3-adrenergic receptor activity research.
References
- 1. Zhang ZB et al.. 2024. Activation of β3-adrenergic receptor by mirabegron prevents aortic dissection/aneurysm by promoting lymphangiogenesis in perivascular adipose tissue.. Cardiovasc Res 120(17):2307-2319 PMID: 39288197
- 2. Cero C et al.. 2021. β3-Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis.. JCI Insight 6(11) PMID: 34100382
- 3. Asif H et al.. 2023. β3 adrenergic receptor activation modulates connexin 43 activity to relax human myometrium.. Cell Signal 106:110640 PMID: 36841274
- 4. Gu W et al.. 2024. β3 adrenergic receptor activation alleviated PM(2.5)-induced hepatic lipid deposition in mice.. Sci Total Environ 907:168167 PMID: 39491202
- 5. do Vale GT et al.. 2019. Three Generations of β-blockers: History, Class Differences and Clinical Applicability.. Curr Hypertens Rev 15(1):22-31 PMID: 30227820
- 6. Schena G et al.. 2021. β3 adrenergic receptor as potential therapeutic target in ADPKD.. Physiol Rep 9(20):e15058 PMID: 34676684
- 7. Dąbrowska AM et al.. 2023. Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.. J Clin Med 12(21) PMID: 37959362
- 8. Cypess AM et al.. 2015. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.. Cell Metab 21(1):33-8 PMID: 25565203
